Study Stopped
not enough patients avalaible
Emotion and Motivation in Patients With Psychosis
Influence of Emotion and Motivation on Behaviour and Neural Activity in Patients With Psychosis
1 other identifier
interventional
41
1 country
1
Brief Summary
Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable schizophrenia
Started Feb 2017
Longer than P75 for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2016
CompletedFirst Posted
Study publicly available on registry
August 2, 2016
CompletedStudy Start
First participant enrolled
February 2, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedAugust 19, 2025
August 1, 2024
8.3 years
May 23, 2016
August 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen
Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.
During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)
Secondary Outcomes (1)
Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen
During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)
Study Arms (2)
Healthy volunteers
SHAM COMPARATORHealthy volunteers
Patients with schizophrenia
EXPERIMENTALPatients with schizophrenia
Interventions
electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
\- clinical scales and subjective assessments of emotional and motivational stimuli
\- clinical scales and subjective assessments of emotional and motivational stimuli
Eligibility Criteria
You may qualify if:
- diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia
You may not qualify if:
- addiction problem
- invalidating visual sensory problems
- neurological history
- for the healthy volunteers: psychiatric history
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unité INSERM 1114
Strasbourg, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2016
First Posted
August 2, 2016
Study Start
February 2, 2017
Primary Completion
June 1, 2025
Study Completion
June 1, 2025
Last Updated
August 19, 2025
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share